The kind of healthcare marketing that people understand

Adage | May 13, 2019

The healthcare industry is in the midst of a revolution as we pivot away from so-called sick care and embrace preventative care, shifting our attention from illness to wellness. Amidst this paradigm change, digital capabilities have given rise to more seamless experiences, and an influx of new data means we can now get more patient-centric than ever before. As those who help shape customer experience in this case, patient experiences we have a tremendous opportunity to leverage the new landscape and the current wellness boom to re-imagine how healthcare feels for patients everywhere.

Spotlight

If there were a vaccine against cancer, would you get it for your kids? HPV is a very common virus, infecting about 14 million people annually. This educational video addresses this importance of adolescents receiving protection against HPV, a cancer-causing disease, and provides an overview of HPV vaccine recommendations. Physicians Julie Boom, MD, Lois Ramondetta, MD, Erich Sturgis, MD, and David Persse, MD, share their expertise, discuss HPV vaccine safety and talk about the importance of HPV vaccination.

Spotlight

If there were a vaccine against cancer, would you get it for your kids? HPV is a very common virus, infecting about 14 million people annually. This educational video addresses this importance of adolescents receiving protection against HPV, a cancer-causing disease, and provides an overview of HPV vaccine recommendations. Physicians Julie Boom, MD, Lois Ramondetta, MD, Erich Sturgis, MD, and David Persse, MD, share their expertise, discuss HPV vaccine safety and talk about the importance of HPV vaccination.

Related News

HEALTHTECH SECURITY

Medtronic Extravascular ICD meets global pivotal clinical trial's safety and effectiveness endpoints

Medtronic plc | August 29, 2022

Medtronic plc a global leader in healthcare technology, today announced that its investigational EV ICD™ System – a first-of-its-kind defibrillator with the lead placed under the breastbone, outside of the heart and veins – achieved a defibrillation success rate of 98.7% and met its safety endpoints in a global clinical trial. Findings from the Extravascular Implantable Cardioverter Defibrillator Pivotal Study were presented as late-breaking science today at the European Society of Cardiology Congress 2022 in Barcelona and simultaneously published in The New England Journal of Medicine. Worldwide, the EV ICD system is investigational and not yet approved for sale or distribution. The Medtronic EV ICD system is designed to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest while avoiding certain risks of traditional, transvenous ICDs because its lead (thin wire) is placed outside the heart and veins, under the breastbone (sternum) using a minimally invasive approach. Placing the lead in this location is designed to help avoid long-term complications that may be associated with leads in the heart and veins, such as vessel occlusion and risks for blood infections. The lead is connected to a device that is implanted below the left armpit. Clinical trial participants received the same therapies provided by traditional ICDs, including defibrillation, anti-tachycardia pacing (ATP), and back-up pacing therapies with this single implanted device that is similar in size, shape, and longevity to traditional ICDs. "We are very encouraged by the high defibrillation effectiveness and strong safety profile of the EV ICD system seen in the study, as we look to deliver less-invasive treatment options for patients at risk of sudden cardiac arrest. These results demonstrate the potential for this novel technology to be used as a safe, successful approach for patients with life-threatening arrhythmias." Ian Crozier, MB, CHB, M.D., Christchurch Hospital, Christchurch, New Zealand, who presented the results at ESC Congress 2022 At six months, 25 major complications were observed in 23 of 316 patients who underwent an implant attempt (7.3%). Twenty-nine patients experienced inappropriate shocks (9.7%, average 10.6 months follow up), most commonly due to P-wave oversensing, which was more frequent in patients implanted early in the study and less frequent among patients implanted later in the study. "These pivotal data mark the start of a new era in ICD therapy for patients who are at significant risk of dangerously fast heart rhythms," said Alan Cheng, M.D., chief medical officer of the Cardiac Rhythm Management business, which is part of the Cardiovascular Portfolio at Medtronic. "Today's findings are an important clinical milestone toward our goal of delivering a one-system, one-procedure extravascular ICD solution that prevents sudden cardiac arrest while improving the patient experience with a smaller device and moving the lead out of the veins and placing it under the breastbone. The EV ICD system retains the benefits of a completely extravascular system while providing ATP, pause prevention pacing and low defibrillation energy." The EV ICD Pivotal study is a prospective, multicenter, single-arm, non-randomized, pre-market clinical study that assessed the safety and effectiveness of the Medtronic EV ICD system for patients at risk of sudden cardiac death. The EV ICD Pivotal study enrolled 356 patients at 46 sites in 17 countries in North America, Europe, the Middle East, Asia, Australia and New Zealand. Medtronic has received FDA approval for a Continued Access Study while the agency reviews the company's EV ICD pre-market application. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for all. In everything we do, we are engineering the extraordinary.

Read More

HEALTH TECHNOLOGY

Amazon and One Medical Sign an Agreement for Amazon to Acquire One Medical

One Medical | July 22, 2022

Amazon and One Medical announced that they have entered into a definitive merger agreement under which Amazon will acquire One Medical. One Medical is a human-centered, technology-powered national primary care organization on a mission to make quality care more affordable, accessible, and enjoyable through a seamless combination of in-person, digital, and virtual care services that are convenient to where people work, shop, and live. “We think health care is high on the list of experiences that need reinvention. Booking an appointment, waiting weeks or even months to be seen, taking time off work, driving to a clinic, finding a parking spot, waiting in the waiting room then the exam room for what is too often a rushed few minutes with a doctor, then making another trip to a pharmacy – we see lots of opportunity to both improve the quality of the experience and give people back valuable time in their days. We love inventing to make what should be easy easier and we want to be one of the companies that helps dramatically improve the healthcare experience over the next several years. Together with One Medical’s human-centered and technology-powered approach to health care, we believe we can and will help more people get better care, when and how they need it. We look forward to delivering on that long-term mission.” Neil Lindsay, SVP of Amazon Health Services “The opportunity to transform health care and improve outcomes by combining One Medical’s human-centered and technology-powered model and exceptional team with Amazon’s customer obsession, history of invention, and willingness to invest in the long-term is so exciting,” said Amir Dan Rubin, One Medical CEO. “There is an immense opportunity to make the health care experience more accessible, affordable, and even enjoyable for patients, providers, and payers. We look forward to innovating and expanding access to quality healthcare services, together.” Amazon will acquire One Medical for $18 per share in an all-cash transaction valued at approximately $3.9 billion, including One Medical’s net debt. Completion of the transaction is subject to customary closing conditions, including approval by One Medical's shareholders and regulatory approval. On completion, Amir Dan Rubin will remain as CEO of One Medical. About Amazon Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Amazon strives to be Earth’s Most Customer-Centric Company, Earth’s Best Employer, and Earth’s Safest Place to Work. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Career Choice, Fire tablets, Fire TV, Amazon Echo, Alexa, Just Walk Out technology, Amazon Studios, and The Climate Pledge are some of the things pioneered by Amazon. About One Medical One Medical is a U.S. national human-centered and technology-powered primary care organization with seamless digital health and inviting in-office care, convenient to where people work, shop, live, and click. One Medical’s vision is to delight millions of members with better health and better care while reducing costs, within a better team environment. One Medical’s mission is to transform health care for all through a human-centered, technology-powered model. Headquartered in San Francisco, 1Life Healthcare, Inc. is the administrative and managerial services company for the affiliated One Medical physician-owned professional corporations that deliver medical services in-office and virtually. 1Life and the One Medical entities do business under the “One Medical” brand.

Read More

HEALTH TECHNOLOGY

Biobeat joins Innovators' Network at American Heart Association Center for Health Technology & Innovation

Biobeat | September 07, 2022

Biobeat, a company focused on remote patient monitoring platforms with artificial intelligence analysis capability, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. The Innovators' Network is a consortium that connects entrepreneurs, providers, researchers and payers. Innovators' Network members also have access to the Association's digital guidelines, recommendations, and best-in-class science as they develop digital healthcare technologies. Members collaborate with the Center in different ways, including the building of models for clinical outcome studies, lowering the significant cost of developing those studies independently, helping connect the science to technology, and providing evidence that a digital platform improves healthcare outcomes – a key concern for providers and payers. "The Center aims to advance the rapid, efficient, and effective development of healthcare technology," said Robert A. Harrington, M.D., FAHA, past president of the American Heart Association (2019-2020), volunteer chair of the American Heart Association's Health Tech Advisory Group for the Center and Arthur L. Bloomfield professor and chair department of medicine, Stanford University. "Joining the Innovators' Network gives members the opportunity to leverage the consortium and work toward broadening and deepening their engagement in this arena." "Biobeat is excited to join the Innovators' Network. It will provide unique access to the Association's research and others innovating in this space, helping us to achieve our goals of improving cardiovascular health and helping health care providers." Arik Eisenkraft, MD, VP Clinical and Regulation at Biobeat About Biobeat Biobeat joins the Innovators' Network bringing with them the Biobeat solution, the first cuffless blood pressure measurement tool to receive FDA clearance. Biobeat leverages health-related artificial intelligence and med-tech capabilities to collect and analyze patient data with a suite of optical-based sensor monitors and machine learning data platforms focused on actionable insights. Wireless sensors worn on the wrist or chest allow remote patient monitoring for blood pressure and multiple physiological parameters. Patient health data is viewed by participating medical staff via Biobeat's secure HIPAA and GDPR compliant cloud-based patient management platform. The platform includes an automated real-time early warning score system that incorporates advanced artificial intelligence algorithms to provide alerts on patient health status. These capabilities are centered on supporting medical teams in providing tailored patient care such as adjustment of therapeutics and early prevention of specific disease exacerbations. The company anticipates that compliance with easy-to-wear cuffless health sensor solutions will help healthcare professionals engage in timely, proactive care for hypertension patients.

Read More